Icon Genetics successfully completes Phase I clinical study with personalized vaccines for treatment of non-Hodgkin's lymphoma
Icon Genetics GmbH (ICON) successfully completed a Phase I clinical study on the safety and immunogenicity of personaliz…
Icon Genetics GmbH (ICON) successfully completed a Phase I clinical study on the safety and immunogenicity of personaliz…
The Council for Scientific and Industrial Research and ICON GENETICS, Munich/Halle, Germany, have announced that they ha…
Icon Genetics GmbH (ICON), Munich/Halle, Germany, a plant biotechnology company, has announced that the Company has been…
Icon Genetics GmbH, Munich, Germany (ICON) and Bayer CropScience have entered into a contract development agreement to c…
Die NOMAD Bioscience GmbH (NOMAD) mit Sitz in München hat eine Reihe von Verträgen mit der Bayer Innovation GmbH, einer…
Die Bayer Innovation GmbH und Kentucky Bioprocessing, LLC (KBP) entwickeln am Standort von KBP in Owensboro im US-amerik…